Academic Journal
Q1Alimentary Pharmacology and Therapeutics
About Alimentary Pharmacology and Therapeutics
Alimentary Pharmacology and Therapeutics is a scholarly journal published by John Wiley and Sons Inc. SCImago 2025 lists it in Q1, with an SJR of 3.006 and H-index of 224.
Coverage: 1987-2026. Research categories: Gastroenterology (Q1); Hepatology (Q1); Pharmacology (medical) (Q1).
Source-backed journal facts
Topics in published research
Inflammatory Bowel Disease; Helicobacter pylori-related gastroenterology studies; Gastrointestinal motility and disorders; Gastroesophageal reflux and treatments; Liver Disease Diagnosis and Treatment; Microscopic Colitis.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
5,250.00 USD; 4,400.00 EUR; 3,480.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Letter: The Q425R Variant in Chronic Hepatitis Delta—Distinguishing Cirrhosis Prevalence From Portal Hypertension Severity
Dandan Weng, Pingping Zhang
2026-10-03 · DOI: 10.1111/apt.71030Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis—From Real‐World Exposure to Indication‐Driven Reassessment. Authors' Reply
Sara Massironi, Marco Vincenzo Lenti, Edith Lahner, Antonio Di Sabatino et al.
2026-10-03 · DOI: 10.1111/apt.71034Letter: Does Adherence‐Selected Follow‐Up Establish the Benefit‐Harm Balance of Population Coeliac Disease Screening? Authors' Reply
Iida Ahonen, Kalle Kurppa, Laura Kivelä, Juha Taavela et al.
2026-10-02 · DOI: 10.1111/apt.71036Letter: P‐CAB Versus PPI for Antithrombotic Gastroprotection: The Importance of Longitudinal Treatment Dynamics—Authors' Reply
Min Joo Yoon, Soyoung Lee, Hye‐Kyung Jung, Min‐ho Kim et al.
2026-10-02 · DOI: 10.1111/apt.71026Editorial: When the Diagnosis is Uncertain, Can AI be Certain Enough?
Rupa Banerjee, Nalini Raghunathan
2026-10-02 · DOI: 10.1111/apt.71025Review Article: Beyond the Therapeutic Ceiling in Inflammatory Bowel Disease—Mechanism‐Based Positioning and Emerging Therapeutic Strategies
Deloshaan Subhaharan, Sreedhar Subramanian
2026-10-02 · DOI: 10.1111/apt.70978Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days
Kajsa Larsson, Kjell Andersson, Gunilla Huledal, Jouni Junnila et al.
2026-10-01 · DOI: 10.1111/apt.70980Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies
Tommaso Lorenzo Parigi, Virginia Solitano, Hailemichael Desalegn Mekonnen, Yuhong Yuan et al.
2026-10-01 · DOI: 10.1111/apt.70998Letter: From Genetic Association to Clinical Prediction in Chronic Hepatitis D
Dandan Weng, Yingying Liu
2026-09-30 · DOI: 10.1111/apt.71029Letter: Sinonasal Microbiota: The Immunological Link Between Eosinophilic Oesophagitis and Chronic Rhinosunisitis?
William Fusco, Laura Bruno, Antonio Gasbarrini, Cristiano Caruso et al.
2026-09-30 · DOI: 10.1111/apt.71027Accelerated Biological Aging in Cholestatic Liver Disease: Telomere Attrition and Association With Disease Severity
Saqr G. Alsakarneh, Brian D. Juran, Jenna Fernandez, Mrinal Patnaik et al.
2026-09-29 · DOI: 10.1111/apt.71013Review Article: Cancer Surveillance for Early Detection of Liver Cancer in Patients with HBV Infection
Andrew J. Park, Bai L. Pan, Xingfei Pan, James Park et al.
2026-09-29 · DOI: 10.1111/apt.71008Revisiting Ferritin‐ IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis
Álvaro Díaz‐González, Bastian Engel, Manuel Hernández‐Guerra, Indhira Pérez‐Medrano et al.
2026-09-28 · DOI: 10.1111/apt.71014Letter: Temporal Alignment of Proton Pump Inhibitor Exposure and Gastric Neuroendocrine Neoplasm Risk in Autoimmune Gastritis. Authors' Reply
Sara Massironi, Marco Vincenzo Lenti, Edith Lahner, Antonio Di Sabatino et al.
2026-09-28 · DOI: 10.1111/apt.71018Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study
Marianne Hupé, Nicolas Mathieu, Aurélien Amiot, Philippe Seksik et al.
2026-09-27 · DOI: 10.1111/apt.70986Letter: Timing Matters—Interpreting Colonic Gas Reduction With Gel‐Forming Fibres
Peng‐Fei Wang
2026-09-27 · DOI: 10.1111/apt.71023Editorial: Beyond the Matrix—Upadacitinib in Real‐World Refractory Crohn's Disease
Iria Bastón‐Rey, Iago Rodríguez‐Lago, Manuel Barreiro‐de Acosta
2026-09-26 · DOI: 10.1111/apt.71019Letter: Proton Pump Inhibitor Prescribing in Autoimmune Gastritis—From Real‐World Exposure to Indication‐Driven Reassessment
Francesco Calabrese, Vincenzo Savarino, Edoardo V. Savarino, Edoardo G. Giannini et al.
2026-09-25 · DOI: 10.1111/apt.71016Reviews
Community Reviews
Version History
September 15, 2026 at 11:45 am
September 15, 2026